Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Cellular Oncology (Dordrecht, Netherlands)|November 21, 2024
HNRNPH1 stabilizes FLOT2 mRNA in a non-canonical m6A-dependent manner to promote malignant progression in nasopharyngeal carcinomaQiguang Li, Jie Liu, Chong Zeng, et al.
Cancer Medicine|March 11, 2020
Identification of hub methylated-CpG sites and associated genes in oral squamous cell carcinomaYuxin Dai, Qiaoli Lv, Tingting Qi, et al.
Frontiers in Immunology|February 21, 2022
A Signature of N6-methyladenosine Regulator-Related Genes Predicts Prognoses and Immune Responses for Head and Neck Squamous Cell CarcinomaJunjun Chen, Tianzhu Lu, Fangyan Zhong, et al.
Scientific Reports|February 18, 2026
MOV10, a novel immunotherapy and prognostic biomarker, contributes to glioma development by regulating autophagyFeiyu Wang, Linlin Ruan, Wenbin Yang, et al.
Frontiers in Pharmacology|June 11, 2025
Anticancer effects of zinc ion-mediated DNA demethylation in oesophageal squamous cell carcinomaBin Zhou, Changchun Wang, Yueyu Huang, et al.
International Journal of Nanomedicine|September 15, 2025
Plasma Small Extracellular Vesicle microRNAs as Non-Invasive Biomarkers for Lung Cancer DetectionQiaoli Lv, Yangzhong Guo, Xiaoya Xu, et al.
Frontiers in Oncology|March 25, 2021
High Expression of Hyaluronan-Mediated Motility Receptor Predicts Adverse Outcomes: A Potential Therapeutic Target for Head and Neck Squamous Cell CarcinomaTianzhu Lu, Yahan Zheng, Xiaochang Gong, et al.
BMC Chemistry|August 27, 2024
Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858RLinxiao Wang, Xiaoling Huang, Shidi Xu, et al.
Oncogenesis|September 27, 2024
NRF2 signaling plays an essential role in cancer progression through the NRF2-GPX2-NOTCH3 axis in head and neck squamous cell carcinomaXiaoye Jin, Xiayuan Lou, Haoxiang Qi, et al.
Archiv Der Pharmazie|February 21, 2024
Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non-small cell lung cancerLei Duan, Cilong Chu, Xiaoling Huang, et al.
Pageof 4